Skip to main content

Increasing Anticancer Drug Internalization Induced by New Au-MWCNTs Nanocomposite

Buy Article:

$107.14 + tax (Refund Policy)

Multi-walled carbon nanotubes (MWCNTs) are found to hold promise in wide range of applications due to their well-known unique properties. However, their applications in biomedicine are still limited by the relative cytotoxicity. In this study, we introduce the biocompatible gold nanoparticles (Au NPs) modified on MWCNTs, forming new stable nanocomposites: Au-MWCNTs. Further, we design a strategy to explore their drug delivery applications and anti-tumor effects by combining with daunorubicin (DNR), using human hepatocarcinoma cells (SMMC-7721 cells) as cancer cells model. Our results show better biocompatibility of Au-MWCNTs than that of MWCNTs. Moreover, compared with DNR treatment alone, when cells treated by Au-MWCNTs together with DNR, obviously increased DNR concentrations in SMMC-7721 cells and anticancer functions are found, which indicates that Au-MWCNTs could be well qualified for efficient delivery carrier importing anticancer agents like DNR into target cells. This strategy develops an avenue to lessen the toxic side-effect of delivery carrier and thus as the promising approach in relevant cancer therapy.

Document Type: Research Article

Publication date: 01 March 2012

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content